INSMED Inc (NASDAQ:INSM)
| Market Cap | 25.51B-16.9% |
| Revenue (ttm) | 1.14B+185.8% |
| Net Income | -875.31M+15.4% |
| EPS | -4.11+28.0% |
| Shares Out | 216.75M |
| PE Ratio | n/a |
| Forward PE | 145.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,744,035 |
| Open | 116.83 |
| Previous Close | 117.83 |
| Day's Range | 116.31 - 119.32 |
| 52-Week Range | 90.39 - 212.75 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 196.33(+66.85%) |
| Earnings Date | Oct 29, 2026 |
INSMED Inc has a live Insider Score.
Scored on 0 qualifying trades from 0 insiders in the last 90 days.
About INSM
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$INSM stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of INSM by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Oct 3, 2025 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Oct 2, 2025 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Sep 22, 2025 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Sep 21, 2025 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Aug 8, 2025 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Aug 7, 2025 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Jul 7, 2025 |
Recently reported changes in INSM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by INSM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
INSM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
INSM Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New INSM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to INSM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in INSM
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $839.59M |
| VXFVanguard Extended Market ETF | $306.79M |
| VBVanguard Morningstar Small-Cap ETF | $303.80M |
| VOVanguard Morningstar Mid-Cap ETF | $285.57M |
| VUGVanguard Morningstar Growth ETF | $217.88M |
| IBBiShares Biotechnology ETF | $196.07M |
Estimated from each fund’s disclosed top holdings × AUM
INSM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from INSM’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score